Safety and Effectiveness of Favipiravir for Novel Coronavirus (COVID-19): A Rapid Review of Available Evidence
Health Technology Assessment in Action · 2021
DOI: 10.18502/htaa.v4i1.5862 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Technology Assessment in Action, 2021. Verfasst von Mohammadreza Mobinizadeh und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Context
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appeared for the first time in December 2019 in Wuhan, China. Due to the lack of unified and integrated evidence for Favipiravir, this study was conducted to rapidly review the existing evidence to help evidence-based decision-making on the therapeutic potential of this drug in the treatment of COVID-19 patients. Evidence Acquisition: This study is a rapid Health Technology Assessment (HTA). By searching pertinent databases, the research team collected relevant articles and tried to create a policy guide through a thematic approach. This rapid review was done in four steps: (1) Searching for evidence through databases; (2) screening the evidence considering eligibility criteria; (3) data extraction; and (4) analyzing the data through thematic analysis.
Results
After applying the inclusion criteria, four studies were finally found, including three review studies and a clinical trial that was temporarily removed by its publisher from the journal’s website. After searching the sources mentioned in the articles, two ongoing clinical trials were found in China. Also, by searching the clinical trial website, www.clinicaltrials.gov, five clinical trials were found in the search. The result of the search in the clinical trial registration system in Iran showed a study that is in the process of patient recruitment. A limited number of other articles were found, mostly in the form of reflections from physicians or researchers and letters to editors who have predicted the drug’s performance on SARS-CoV-2, which needs further clinical study to be approved.
Conclusions
With the available evidence, it is not possible to make a definite conclusion about the safety and efficacy of Favipiravir in the treatment of patients with COVID-19.
Zitieren
APA
Mobinizadeh, M., & Arab-Zozani, M. (2021). Safety and Effectiveness of Favipiravir for Novel Coronavirus (COVID-19): A Rapid Review of Available Evidence. Health Technology Assessment in Action. https://doi.org/10.18502/htaa.v4i1.5862
Vancouver
Mobinizadeh M, Arab-Zozani M. Safety and Effectiveness of Favipiravir for Novel Coronavirus (COVID-19): A Rapid Review of Available Evidence. Health Technology Assessment in Action. 2021. doi:10.18502/htaa.v4i1.5862
BibTeX
@article{Mobinizadeh2021,
author = {Mobinizadeh, Mohammadreza and Arab-Zozani, Morteza},
title = {Safety and Effectiveness of Favipiravir for Novel Coronavirus (COVID-19): A Rapid Review of Available Evidence},
journal = {Health Technology Assessment in Action},
year = {2021},
doi = {10.18502/htaa.v4i1.5862}
}
EUVIMED